| 1 | Reinforcement Learning Approach for Treatment Decisions in NSCLC | Bozcuk HŞ, et al. | Cancers (Basel) | 2025 | - |
| 2 | Efficacy and safety of ICIs in Turkish patients with metastatic melanoma | Ozgun A, et al. | Mol Clin Oncol | 2025 | - |
| 3 | Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer | Forde PM, et al. | N Engl J Med | 2025; 393(8) | 741-752 |
| 4 | Paraneoplastic vocal cord paralysis after nivolumab | Erdoğan S, et al. | J Neuroimmunol | 2025 | - |
| 5 | Real-World Outcomes in BRAF-Mutant NSCLC (TOG Analysis) | Telli TA, et al. | Clin Lung Cancer | 2025 | - |
| 6 | PACIFIC-2 Study: Simultaneous Durvalumab and CRT in Stage III NSCLC | Bradley JD, et al. | J Clin Oncol | 2025 | - |
| 7 | Adjuvant CRT plus DCF versus FUFA in Stage III Gastric Cancer | Alkan A, et al. | J Cancer Res Ther | 2024 | 1 |
| 8 | Long-term outcomes of IMRT in limited-stage small-cell lung cancer | Bırgı SD, et al. | Eur Rev Med Pharmacol | 2024; 28 | 1562-74 |
| 9 | Efficacy and safety of nivolumab in metastatic NSCLC in Türkiye | Karadurmus N, et al. | Curr Med Res Opin | 2024; 40(7) | 1171-8 |
| 10 | Treatment outcomes in driver mutant NSCLC and brain metastases | Kahraman S, et al. | Scientific Reports | 2024; 14 | - |
| 11 | Impact of low sodium values on survival in patients receiving ICIs | Karaoğlan BB, et al. | Immunotherapy | 2024 | - |
| 12 | Impact of antihistamine use on survival outcomes of ICIs | Mocan EE, et al. | Anti-Cancer Drugs | 2024; 35(2) | 190-4 |
| 13 | XRCC1 and TP53 polymorphisms in advanced-stage NSCLC | Karaağaç M, et al. | J Cancer Res Ther | 2023; 19(5) | 1248-54 |
| 14 | Prognostic significance in pleural involvement in ALK-positive NSCLC | Güner G, et al. | J Cancer Res Clin Oncol | 2023; 149 | 13271-7 |
| 15 | Clinicopathological parameters and PD-L1 expression level in NSCLC | Gurbuz M, et al. | Tuberk Toraks | 2022 | - |
| 16 | Impact of antihistamines use on immune checkpoint inhibitors response | Yekedüz E, et al. | Anti-Cancer Drugs (Onc.) | 2022 | - |
| 17 | Atezolizumab combined with chemotherapy in ES-SCLC | Gürbüz M, et al. | J Cancer Res Clin Oncol | 2022 | 1-9 |
| 18 | Evaluation of treatment response in ALK mutant NSCLC | Dogan I, et al. | Medicine | 2022 | - |
| 19 | Chronic hyperglycemia and decreased survival in patients treated with ICIs | Yekedüz E, et al. | Anti-Cancer Drugs | 2022 | - |
| 20 | Real Life Clinical Outcomes of PDL-1 Tested Patients with NSCLC | Yazici O, et al. | J Thorac Oncol | 2022 | S348 |
| 21 | Lung Cancer in Turkey | Cangır AK, Demirkazık A. | J Thorac Oncol | 2022; 17 | 1158-1170 |
| 22 | Seasonal Influenza and Pneumococcal Vaccination Rates in COVID-19 | Yekedüz E, et al. | J Oncol Sci | 2021; 7(2) | 64-70 |
| 23 | Comparison of Afatinib and Erlotinib in Rare EGFR Mutations NSCLC | Gürsoy P, et al. | J Cancer Res Clin Oncol | 2021 | - |
| 24 | Efficacy and safety of osimertinib in T790M mutation NSCLC | Hizal M, et al. | J Cancer Res Clin Oncol | 2021 | - |
| 25 | Blood Type and EGFR Mutation Positivity in Lung Adenocarcinoma | Gürbüz M, et al. | J Oncol Sci | 2021 | - |
| 26 | Afatinib versus first-gen TKIs in EGFR exon 19 deletion NSCLC | Bilgin B, et al. | J Cancer Res Clin Oncol | 2021 | - |
| 27 | Durvalumab ± tremelimumab plus platinum-etoposide in ES-SCLC | Goldman JW, et al. | Lancet Oncol | 2021; 22(1) | 51-65 |
| 28 | ERCC1 and XRCC1 SNPs in metastatic non-small cell lung cancer | Karaagac M, et al. | Medicine Science | 2020; 9(1) | 255-60 |
| 29 | Loneliness and Cancer Diagnosis on Cognitive Impairment in Geriatric Patients | Alkan A, et al. | J Oncol Sci | 2020; 6(2) | 65-70 |
| 30 | Sleep Quality of Cancer Patients Receiving Systemic Treatment | Tunca Şanlıer N, et al. | J Oncol Sci | 2020; 6(1) | 15-22 |
| 31 | Osteopontin is a prognostic factor in patients with advanced gastric cancer | Yazici O, et al. | Comb Chem High Throughput Screen | 2020 | - |
| 32 | GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Study | Peled N, et al. | Lung Cancer | 2020; 148 | 48-54 |
| 33 | Durvalumab plus platinum-etoposide in ES-SCLC (CASPIAN trial) | Paz-Ares L, et al. | Lancet | 2019; 394 | 1929-1939 |
| 34 | 68Ga-DOTATATE Uptake in Pancreatic Metastasis of RCC | Soydal C, Demirkazik A. | Clin Nucl Med | 2019; 44(10) | 795-796 |
| 35 | Serum Cytokine and VEGF Levels Following Chemotherapy | Keskin H, et al. | Biomark Cancer | 2019 | - |
| 36 | Erlotinib first line treatment in EGFR mutation-positive lung adenocarcinoma | Markóczy Z, et al. | BMC Cancer | 2018; 18(1) | 598 |
| 37 | Diagnostic serum vitamin D level in resectable breast cancer | Mizrak Kaya D, et al. | Future Oncol | 2018; 14(15) | 1461-1467 |
| 38 | Alectinib versus Crizotinib in Untreated ALK-Positive NSCLC | Peters S, et al. | N Engl J Med | 2017; 377(9) | 829-838 |
| 39 | Significance of serum leptin level in patients with early stage NSCLC | Karatas F, et al. | J Cancer Res Ther | 2017; 13(2) | 204-207 |
| 40 | Vaccination in oncology practice and predictors | Alkan A, et al. | Support Care Cancer | 2017; 25(9) | 2677-2682 |
| 41 | Fight of Turkish medical oncologists against cancer (TSMO & TOG) | H.Abali, A. Demirkazik. | J Oncol Sci | 2017; 3 | - |
| 42 | Turkish doctors' cohort: healthy despite low screening | Unal S, et al. | Postgrad Med | 2016 | 1-6 |
| 43 | Docetaxel-induced pericardial effusion | Dogan SE, Demirkazik A. | J Oncol Pharm Pract | 2016 | - |
| 44 | Using Interferon Alfa Before TKIs in Metastatic RCC (TOG Study) | Artaç M, et al. | Clin Genitourin Cancer | 2016; 14(4) | e347-53 |
| 45 | Turkish medical oncology society looks forward | Ahmet Demirkazık. | J Oncol Sci | 2016 | - |
| 46 | Molecular spectrum of PIK3CA gene mutations in NSCLC | Ekinci S, et al. | Genet Test Mol Biomarkers | 2015; 19(7) | 353-8 |
| 47 | Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 SNPs in NSCLC | Geredeli C, et al. | Tumour Biol | 2015 | - |
| 48 | Cardiac biomarkers as predictors of trastuzumab cardiotoxicity | Urun Y, et al. | Exp Oncol | 2015; 37(1) | 53-7 |
| 49 | The current and future role of the medical oncologist (ESMO position paper) | Popescu RA, et al. | Annals of Oncology | 2014; 25 | - |
| 50 | EGFR, BRAF, KRAS Mutations and Prognosis in Advanced NSCLC | Mutlu Dogan, et al. | UHOD | 2014; 24(1) | - |
| 51 | Association of ABO blood group and risk of lung cancer | Urun Y, et al. | Asian Pac J Cancer Prev | 2013; 14(5) | 2801-3 |
| 52 | Influenza and pneumococcal vaccines coverage among cancer patients | Y. Urun, H. Akbulut, et al. | JBUON | 2013; 18(2) | 511-515 |
| 53 | Intraabdominal follicular dendritic cell sarcoma: review of literature | Yuksel Urun, et al. | Tumori | 2013; 99(2) | e65-9 |
| 54 | Albumin Infusion is not Beneficial in Hypoalbuminemic End-Stage Cancer Patients | Buyukcelık A, et al. | UHOD | 2012; 22(4) | 213-219 |
| 55 | Antimetabolite toxicity and pharmacogenetics in Turkish cancer patients | Dogan M, et al. | Asian Pac J Cancer Prev | 2012; 13(4) | 1553-6 |
| 56 | Adjuvant EoP following sequential AC and Docetaxel in early breast cancer | Fikri Icli, et al. | The Breast | 2011; 20 | 155-157 |
| 57 | Fifty-one Kaposi sarcoma patients | Mutlu Dogan, et al. | Clin Transl Oncol | 2010; 12 | 629-633 |
| 58 | Implementation of NCCN Guidelines on NSCLC in MENA Region | Jazieh AR, Demirkazık A, et al. | J Natl Compr Canc Netw | 2010; 8 | - |
| 59 | Prognostic Importance of Leucocytosis, Thrombocytosis and Serum VEGF in NSCLC | Ahmet Demirkazık, et al. | Int J Hematol Oncol | 2010; 20(1) | - |
| 60 | The WHO global alliance against chronic respiratory diseases in Turkey (GARD) | Yorgancioğlu A, et al. | Tuberk Toraks | 2009; 57(4) | 439-52 |
| 61 | Myoid Hamartoma of the Breast: A Very Rare Entity | Bayar S, Düşünceli E, et al. | Breast J | 2009 | - |
| 62 | Cetuximab plus chemotherapy in advanced NSCLC (FLEX trial) | 186 Collaborators. | Lancet | 2009; 373 | 1525-31 |
| 63 | Effects of Genomic Imbalances on Telomerase Activity in Gastric Cancer | Akay G. G, Elhan A. H, et al. | Oncology Research | 2009; 17 | 455-462 |
| 64 | Long-term outcome of MINE regimen as consolidation in aggressive NHL | Dincol D, Buyukcelik A, et al. | Med Oncol | 2009 | - |
| 65 | Role of ABCB1 and ABCC1 gene induction on survival in breast cancer | Atalay C, Demirkazık A, et al. | J Chemother | 2008; 20(6) | 734-9 |
| 66 | Impact of operation center on outcome of stage II/III colorectal cancer | Büyükçelik A, Akbulut H, et al. | Turkish Journal of Cancer | 2008; 38(4) | - |
| 67 | Prognostic Significance of Serum MMP-9 Levels in Patients with Sarcomas | Yaman A, Yalçın B, et al. | Int J Hematol Oncol | 2008; 18(2) | - |
| 68 | A metastatic liver tumour with unusual cytological findings | Ceyhan K, Ustuner E, et al. | Cytopathology | 2008 | - |
| 69 | MRI of non-neoplastic cranial complications of malignant disorders | Yağmurlu B, Akyürek S, et al. | Diagn Interv Radiol | 2008; 14(2) | 61-8 |
| 70 | Venous thromboembolism and relationship to coagulation cascade and VEGF | Dogan M, Demirkazik A. | Support Cancer Ther | 2008; 3(1) | 28-34 |
| 71 | Clinical benefit response from second-line chemotherapy in gastric adenocarcinoma | Sencan O, Buyukcelik A, et al. | Eur J Cancer Care | 2008; 17(1) | 26-32 |
| 72 | LMWH increases the efficacy of cisplatinum plus gemcitabine in pancreatic cancer | Icli F, Akbulut H, et al. | J Surg Oncol | 2007; 95(6) | 507-12 |
| 73 | Lung cancer metastasis mimicking gluteal abscess | Tek I, Iyidir OT, et al. | South Med J | 2007; 100(3) | 334-5 |
| 74 | Ultrasound-guided percutaneous laser ablation in anaplastic thyroid carcinoma | Cakir B, Topaloglu O, et al. | J Endocrinol Invest | 2007; 30(7) | 624-5 |
| 75 | Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma | Utkan G, Büyükçelik A, et al. | Lung Cancer | 2006; 53(3) | 367-74 |
| 76 | Venous thromboembolism on survival and its relationship with serum VEGF | Dogan M, Demirkazik A, et al. | Int J Biol Markers | 2006; 21(4) | 206-10 |
| 77 | Cisplatin plus oral etoposide (EoP) versus paclitaxel in advanced breast cancer | Icli F, Akbulut H, et al. | Br J Cancer | 2005; 92(4) | 639-44 |
| 78 | Interferon-alpha as maintenance therapy in patients with multiple myeloma | Yalcin B, Dogan M, et al. | Ann Oncol | 2005; 16(12) | 1981 |
| 79 | Combination chemotherapy of gemcitabine and vinorelbine in NSCLC | Buyukcelik A, Utkan G, et al. | Lung Cancer | 2004; 46(3) | 377-8 |
| 80 | High-dose ifosfamide with hematopoietic growth factor support in sarcomas | Yalcin B, Pamir A, et al. | Exp Oncol | 2004; 26(4) | 320-5 |
| 81 | Serum VEGF levels in patients with non-small cell lung cancer | Demirkazik A, Akbulut H, et al. | Ann Saudi Med | 2004; 24(6) | 473-5 |
| 82 | Activity of CPD combination in advanced colorectal carcinoma | Akbulut H, Icli F, Yalcin B, et al. | Eksp Onkol | 2004; 26(2) | 149-52 |
| 83 | Effect of prior therapy on progenitor cell content of blood stem cell harvests | Demirkazik A, Kessinger A, et al. | Biol Blood Marrow Transplant | 2002; 8(5) | 268-72 |
| 84 | Respiratory distress due to endotracheal aspergilloma in lymphoma patient | Kavgaci H, Boruban MC, et al. | J Chemother | 2002; 14(1) | 92-4 |
| 85 | Prognostic significance of blood group antigen expression in lung cancer | Ulger AF, Keklik T, et al. | Tumori | 2002; 88(5) | 395-9 |
| 86 | Progenitor and lymphoma cells in blood stem cell harvests: impact on survival | Demirkazik A, Kessinger A, et al. | Bone Marrow Transplant | 2001; 28(2) | 207-12 |
| 87 | A randomized trial of four cycles of adjuvant AC +/- two cycles of EP | Icli F, Akbulut H, Dincol D, et al. | Ann Oncol | 2001; 12(7) | 1011-3 |
| 88 | Comparison of morning versus night administration of GM-CSF | Dincol D, Samur M, Pamir A, et al. | Cancer | 2000; 88(9) | 2033-6 |
| 89 | The effect of two different doses of oral clodronate on pain in patients with bone metastases | Arican A, Icli F, Akbulut H, et al. | Med Oncol | 1999; 16(3) | 204-10 |
| 90 | Clinicopathologic features and prognostic factors of primary extranodal NHL | Arıcan A, Dinçol D, Akbulut H, et al. | Am J Clin Oncol | 1999; 22(6) | 587-92 |
| 91 | Relationship between serum concentration of VEGF and tumor stage in breast cancer | Eroğlu A, Demirkazık A, Akbulut H, et al. | Journal of BUON | 1999; 4 | 83-85 |
| 92 | A phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma... | Içli F, Arıcan A, Çay F, et al. | Oncology | 1999; 56 | 297-300 |
| 93 | A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-FU... | İçli F, Çelik İ, Aykan F, et al. | Cancer | 1998; 83 | 2475-80 |
| 94 | Effects of high dose medroxyprogesterone acetate on endogenous GM-CSF secretion... | Aydın F, Demirkazık A, İçli F, et al. | J Chemotherapy | 1998; 10(5) | 394-398 |
| 95 | Diagnostic value of ferritin in the differential diagnosis of malignant effusions | Demirkazık A, Dinçol D, Hastürk S, et al. | Cancer Biochem Biophys | 1998; 16 | 243-251 |
| 96 | Results of CHOP ± bleomycin treatment and evaluation of prognostic factors... | Dinçol D, Akbulut H, İçli F, et al. | Oncology | 1997; 54 | 376-379 |
| 97 | A phase II study of modified combination of etoposide, doxorubicin and cisplatin... | İçli F, Karaoğuz H, Akbulut H, et al. | J Surg Oncol | 1997; 64 | 318-323 |
| 98 | Two dose levels of ifosfamide in malignant mesothelioma | İçli F, Karaoğuz H, Hastürk S, et al. | Lung Cancer | 1996; 15 | 207-213 |
| 99 | MINE-BOP combination chemotherapy in the treatment of refractory and relapsed NHL | Dinçol D, İçli F, Karaoğuz H, et al. | Acta Oncol | 1995; 34(7) | 937-940 |
| 100 | Severe vascular toxicity associated with cisplatin based chemotherapy | İçli F, Karaoğuz H, Dinçol D, et al. | Cancer | 1993; 72(2) | 587-593 |
| 101 | Primary gastrointestinal lymphomas in Turkey: A retrospective analysis... | Dinçol D, İçli F, Erekul S, et al. | J Surg Oncol | 1992; 51 | 270-273 |
| 102 | Cisplatin plus VP16 combination chemotherapy in advanced refractory breast cancer | İçli F, Günel N, Dinçol D, et al. | J Surg Oncol | 1992; 50 | 251-253 |
| 103 | Treatment of metastatic malignant melanoma with 24 hours continous venous infusion... | İçli F, Karaoğuz H, Dinçol D, et al. | J Surg Oncol | 1991; 48 | 199-201 |
| 104 | Tuberculous peritonitis: Ultrasonic diagnosis | Akhan O, Demirkazık F, Demirkazık A, et al. | J Clin Ultrasound | 1990; 18 | 711-714 |
| 105 | Cyclosporin for refractory aplastic anemia | Dündar S, Demirkazık A. | Acta Haematol | 1990; 83 | 112 |